Mount Vernon Cancer Centre Becomes First NHS Facility to Acquire a CyberKnife System

Government Purchase Enhances Patient Access to Whole Body Radiosurgery

SUNNYVALE, California, February 15, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that Mount Vernon Cancer Centre in the United
Kingdom has become the first National Health Service (NHS) hospital to
acquire a CyberKnife(R) Robotic Radiosurgery System.

The NHS has grown to become the world's largest publicly funded health
service. The system was born just over 60 years ago out of a long-held ideal
that quality healthcare should be available to all, regardless of wealth -
and that principle remains at its core. The NHS remains free at the point of
use for anyone who is a resident in the United Kingdom - more than 60 million
people - with only a few minor exceptions, and is funded centrally from
national taxation.

"Patients have been very eager to see CyberKnife radiosurgery available
through the National Health Service, so we are excited to soon be able to
offer them this state-of-the-art form of cancer care," said Dr. Peter Ostler,
Consultant Clinical Oncologist and the Trust's Clinical Chair for Cancer
Services. "The CyberKnife System will enable us to expand our radiation
offerings to patients who may not have been able to tolerate other treatments
or have medically or surgically inoperable tumors."

The CyberKnife System uses real-time tracking capabilities to deliver
high-dose radiation to tumors with pin-point accuracy, including tumors that
move with respiration. As a non-invasive treatment for cancerous and
non-cancerous tumors, the CyberKnife System does not require the use of
stabilizing frames or uncomfortable breath holding techniques, making it an
easy and comfortable experience for the patient. Treatments are typically
completed in one to five days and patients can resume their normal activities
immediately following treatment.

"Mount Vernon Cancer Centre has a strong reputation for cancer treatment,
particularly using radiation, so it is great to see their treatment arsenal
strengthened with the purchase of a CyberKnife System," said Euan S. Thomson,
Ph.D., president and CEO of Accuray Incorporated. "We are proud to be working
with the East and North Hertfordshire NHS Trust and are very pleased with
their recognition of the CyberKnife System's unique contributions in the
treatment of cancer."

East and North Hertfordshire NHS Trust manages four hospitals, including
The Mount Vernon Cancer Centre. As one of the UK's top five cancer treatment
centers, The Mount Vernon Cancer Centre, which is located in North-west
London, provides specialist tertiary radiotherapy services, as well as a
local chemotherapy service.

About the Mount Vernon Cancer Centre

The Mount Vernon Cancer Centre, managed by the East and North
Hertfordshire NHS Trust, has been based in Northwood, North-west London for
many years and is a leading cancer center, treating around 5,000 new patients
per annum. More than 3,000 new patients a year are treated with radiotherapy,
with an additional 1,500 receiving chemotherapy (mainly from people living
closer to the cancer center). It serves a population of two million people
living in North-west London, Hertfordshire and parts of the Thames Valley.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 80,000 patients
worldwide and currently more than 190 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
commercialization of products, clinical studies, and regulatory review and
approval are forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements speak only as of the date the statements are made
and are based on information available at the time those statements are made
and/or management's good faith belief as of that time with respect to future
events. You should not put undue reliance on any forward-looking statements.
Important factors that could cause actual performance and results to differ
materially from the forward-looking statements we make include: market
acceptance of products; competing products, the combination of our products
with complementary technology; and other risks detailed from time to time
under the heading "Risk Factors" in our report on Form 10-K for the 2009
fiscal year, our quarterly report on Form 10-Q filed on February 4, 2010 and
our other filings with the Securities and Exchange Commission. The Company's
actual results of operations may differ significantly from those contemplated
by such forward-looking statements as a result of these and other factors. We
assume no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

    Available Topic Expert(s): For information on the listed expert(s), click
    appropriate link.
    Euan Thomson, Ph.D.
    https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

Stephanie Tomei, Senior Manager, Marketing Communications, +1-408-789-4234, stomei at accuray.com, or Sancie Nakarat, Manager, EU Marketing, +33-6-81-36-84-34, snakarat at accuray.com, both of Accuray